Stockscreener 앱 받기
5.36
3.68%
-0.205
Kyntra Bio Inc 주식(KYNB)의 최신 뉴스
Kyntra Bio sought Nasdaq review and Kyntra Bio stock costs EUR 5.45 - AD HOC NEWS
Kyntra Bio Faces Nasdaq Delisting, Appeals Listing Decision - The Globe and Mail
Form 4 Kyntra Bio Inc For: 6 October By Investing.com - Investing.com UK
A director receives 14,000 Kyntra Bio (KYNB) stock options with a $6.50 exercise price. - Stock Titan
Kyntra Bio Received Notice of Delisting - TradingView
Form 4 Kyntra Bio Inc For: 6 October By Investing.com - Investing.com Nigeria
Kyntra Bio Appoints Andrew E. Singer, MBA to its Board of Directors - GlobeNewswire Inc.
FibroGen stock trades at USD 6.94 after Kyntra Bio rebrand - AD HOC NEWS
Kyntra Bio (KYNB) CEO reports RSU tax withholding, not a stock sale - Stock Titan
Kyntra Bio (KYNB) CFO holds 4,355 shares after tax withholding - Stock Titan
KIN stock holds steady as Kyntra Bio prepares new earnings update - ad-hoc-news.de
Kyntra Bio to Present at H.C. Wainwright 28th Annual Global Investment Conference - Quiver Quantitative
A drug company's CEO will present in New York Sept. 15. Kyntra Bio will webcast it. - stocktitan.net
Kyntra Bio to Present at the H.C. Wainwright 28th Annual Global Investment Conference - Yahoo Finance
KYNB Reiterated by HC Wainwright & Co. -- Price Target Maintained at $43 - GuruFocus
Oppenheimer reiterates Kyntra Bio stock rating on debt reduction - Investing.com
Oppenheimer reiterates Kyntra Bio stock rating on debt reduction By Investing.com - Investing.com South Africa
Kyntra Bio Streamlines Financing, Strengthens Balance Sheet - TipRanks
KYNB Looks 65.5% Overvalued on GF Value™ - GuruFocus
Kyntra Bio Cuts Royalty Payments to NQ Project Phoebus for Accelerated Upfront Payment - marketscreener.com
Kyntra Bio Amends Revenue Interest Deal With NQ Project Phoebus, Cuts Cap to $65M, Pays $42.6M - TradingView
Kyntra Bio Continues Balance Sheet Transformation with Material Reduction of Royalty Financing Obligation - marketscreener.com
Kyntra Bio Continues Balance Sheet Transformation with Material Reduction of Royalty Financing Obligation - GlobeNewswire
Kyntra Bio Continues Balance Sheet Transformation with Material Reduction of Royalty Financing Obligation - finance.yahoo.com
Kyntra Bio (KYNB) Edges Higher to $8.02, Up 0.25% as Stock Holds Between Key LevelsSupply Zone - dars.gov.et
Enterprise value to revenue forward of Kyntra Bio, Inc. – BX:KYNB - TradingView
Kyntra Bio (KYNB) Q2 2026 Earnings Call Transcript - AOL.com
Kyntra Bio Inc (KYNB) (Q2 2026) Earnings Call Highlights: Advanc - GuruFocus
Kyntra Bio, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:KYNB) 2026-08-16 - Seeking Alpha
Kyntra Bio Confronts Nasdaq Listing Risk as Asset and Revenue Shortfall Threatens Global Select Status - TipRanks
Kyntra Bio, Inc. (NASDAQ: KYNB) Stock Price, News & Analysis - kalkine.ca
Kyntra Bio Inc. (KYNB) Holds Above Key Support After Modest PullbackSector Neutral Pair - vinanet.vn
Kyntra Bio, Inc. (NASDAQ: KYNB) Stock Price, News & Analysis - Kalkine
Armistice Capital (KYNB) discloses 400,000-share, 9.88% Kyntra Bio position - Stock Titan
Kyntra Bio Inc. (KYNB) Holds Above Key Support After Modest PullbackPut Spread Alert - dars.gov.et
Kyntra Bio Inc Q2 Net Income From Cont Ops US - moomoo.com
KYNB Looks 28.4% Overvalued on GF Value™ - GuruFocus
Kyntra Bio Q2 adj. EPS $(4.68) misses $(3.18) estimate - scanx.trade
Kyntra Bio Q2 2026 slides: dual catalysts expected, cash into 2028 - Investing.com
Kyntra Bio Q2 2026 slides: prostate cancer, MDS programs eye Q4 catalysts - Investing.com
Earnings call transcript: Kyntra Bio rises as pipeline updates offset weak Q2 2026 sales - Investing.com
Kyntra Bio Q2 2026 Earnings Call: Complete Transcript - Benzinga
KYNB: Q2 2026 marked clinical progress and a return to profitability, with cash runway into 2028 - TradingView
Kyntra Bio (KYNB) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Kyntra Bio, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
KYNTRA BIO ($KYNB) Releases Q2 2026 Earnings - Quiver Quantitative
Is Kyntra Bio Inc (KYNB) Facing Challenges After Q2 Earnings Mis - GuruFocus
Kyntra Bio: Q2 Earnings Snapshot - marketscreener.com
Kyntra Bio: Q2 Earnings Snapshot - aol.com
Kyntra Bio: Q2 Earnings Snapshot - KTVB
1.35%
자본화:
|
볼륨(24시간):